Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Cash from Financing Activities: 2022-2025

Historic Cash from Financing Activities for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Sep 2025 value amounting to $3.4 million.

  • Centessa Pharmaceuticals' Cash from Financing Activities fell 98.60% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 96.99%. This contributed to the annual value of $364.8 million for FY2024, which is 1627.29% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Cash from Financing Activities is $3.4 million, which was up 114.14% from $1.6 million recorded in Q2 2025.
  • Over the past 5 years, Centessa Pharmaceuticals' Cash from Financing Activities peaked at $246.0 million during Q3 2024, and registered a low of $12,000 during Q2 2023.
  • For the 3-year period, Centessa Pharmaceuticals' Cash from Financing Activities averaged around $39.4 million, with its median value being $4.9 million (2023).
  • In the last 5 years, Centessa Pharmaceuticals' Cash from Financing Activities spiked by 877,508.33% in 2024 and then plummeted by 98.60% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Cash from Financing Activities (Quarterly) stood at $89,000 in 2022, then soared by 7,047.19% to $6.4 million in 2023, then tumbled by 53.42% to $3.0 million in 2024, then plummeted by 98.60% to $3.4 million in 2025.
  • Its Cash from Financing Activities was $3.4 million in Q3 2025, compared to $1.6 million in Q2 2025 and $3.1 million in Q1 2025.